Ercole Biotech, Inc.;Santaris Pharma A/S;The University of North Carolina at Chapel Hill
发明人:
Sazani, Peter L.,Kole, Ryszard,Orum, Henrik,Graziewicz, Maria
申请号：
AU2019204272
公开号：
AU2019204272A1
申请日:
2019.06.18
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2019204272A120190718.pdf#####Abstract. The present invention is directed to tumour necrosis factor (TNF) antagonists and corresponding nucleic acids, expression vectors and cells, in the treatment of inflammatory disease such as psoriasis, arthritis, Crohn,s disease hepatitis alcoholic liver disease and non-alcoholic steatosis. These antagonists being derived from TNF receptors, and are soluble secreted decoy receptors. In particular the antagonists are mammalian TNFR receptors lacking exon 7, which can bind TNF and act as an antagonist. The present invention is also directed to splice switching oligomers (SSOs), wherein these SSOs alter tumour necrosis factor receptor 2 (TNFR2) pre-mRNA splicing to increase production of a protein capable of binding TNF.
